公开(公告)号：EP1874726A2

公开(公告)日：2008-01-09

申请号：EP06742574.4

申请日：2006-04-12

申请人： Novartis AG ,  NOVARTIS-PHARMA GMBH ,  IRM, LLC

发明人： DANAHAY, Henry L., Novartis Horsham Research Ctr ,  LEGRAND, Darren M., Novartis Horsham Research Ctr ,  TULLY, David, C. ,  HARRIS, Jennifer, Leslie ,  HEUERDING, Silvia ,  SINGH, Dilraj ,  MAAS, Janet C.,Novartis Horsham Research Ctr ,  ROETTELE, Juergen ,  REBER, Jean-Louis ,  MONNIER, Stéphanie

IPC分类号： C07C279/18 ,  C07C277/08 ,  A61K9/19 ,  A61K31/24

CPC分类号： A61K9/19 ,  C07C279/18

摘要： The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).

摘要翻译： 本发明描述了卡莫司他的新的药学上可接受的盐形式，用于冷冻干燥的方法，掩味制剂，雾化制剂和前列腺治疗呼吸系统疾病，特别是囊性纤维化和慢性阻塞性肺病（COPD） 。

公开(公告)号：EP1874726B1

公开(公告)日：2012-05-16

申请号：EP06742574.4

申请日：2006-04-12

申请人： Novartis AG ,  IRM LLC

发明人： DANAHAY, Henry L. ,  LEGRAND, Darren M. ,  TULLY, David, C. ,  HARRIS, Jennifer, Leslie ,  HEUERDING, Silvia ,  SINGH, Dilraj ,  MAAS, Janet C. ,  ROETTELE, Juergen ,  REBER, Jean-Louis ,  MONNIER, Stéphanie

IPC分类号： C07C279/18 ,  C07C277/08 ,  A61K9/19 ,  A61K31/24

CPC分类号： A61K9/19 ,  C07C279/18

摘要： The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).

公开(公告)号：EP2229148A1

公开(公告)日：2010-09-22

申请号：EP08859412.2

申请日：2008-12-11

申请人： Novartis AG

发明人： MUHRER, Gerhard ,  KIECKBUSCH, Thomas ,  SINGH, Dilraj ,  THAKUR, Ranjit ,  SCHAFFLUETZEL, Kurt ,  RASENACK, Norbert

IPC分类号： A61K9/14

CPC分类号： A61K9/145 ,  A61K9/0075 ,  A61K9/008 ,  A61K31/40

摘要： A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 μm, and drying the drug particles to remove any residual anti-solvent.

公开(公告)号：EP2229148B1

公开(公告)日：2014-03-05

申请号：EP08859412.2

申请日：2008-12-11

申请人： Novartis AG

发明人： MUHRER, Gerhard ,  KIECKBUSCH, Thomas ,  SINGH, Dilraj ,  THAKUR, Ranjit ,  SCHAFFLUETZEL, Kurt ,  RASENACK, Norbert

IPC分类号： A61K9/14

CPC分类号： A61K9/145 ,  A61K9/0075 ,  A61K9/008 ,  A61K31/40

公开(公告)号：EP1917200A1

公开(公告)日：2008-05-07

申请号：EP06792719.4

申请日：2006-08-04

申请人： Novartis AG

发明人： SINGH, Dilraj ,  PROVOT, Gerard

IPC分类号： B65D81/38 ,  B65D83/14 ,  A61M15/00

CPC分类号： A61M15/009 ,  A61M2202/064 ,  A61M2205/0233 ,  A61M2205/3633 ,  B65D83/38

摘要： An insulated canister for, pressurized or non-pressurized systems, use with a metered dose system for example, a metered dose inhaler or topical aerosol featuring an inner container surrounded by an outer container with a gap defined by the space between the walls of the inner and outer container. Such gap can be filled by a vacuum, air or material with low thermal conductivity.